Xilio Therapeutics's top three insider shareholders as of June 18, 2026 are Sciences, Inc. Gilead (TenPercentOwner, 9.11Mn shares), Impact Medicine Fund Lp Sv7 (TenPercentOwner, 3.23Mn shares), Capital Life Sciences Investors, Llc Bain (TenPercentOwner, 2.81Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Llc Fmr | - | 0 | 1,907,670 | 28 Oct, 2021 |
| Ltd Fil | - | 0 | 218,705 | 28 Oct, 2021 |
| Sciences, Inc. Gilead | - | 9,105,451 | 0 | 19 Dec, 2024 |
| City Capital Llc Bay | - | 0 | 1,129,490 | 26 Oct, 2021 |
| James E Flynn | - | 0 | 2,287,944 | 28 Oct, 2021 |
| Pharmaceutical Co Ltd Takeda | - | 0 | 1,475,121 | 26 Oct, 2021 |
| James Samuel Shannon | - | 10,000 | 0 | 30 Mar, 2026 |
| Springs Capital Management Lp Rock | - | 0 | 1,256,472 | 26 Oct, 2021 |
| Capital Life Sciences Investors, Llc Bain | - | 0 | 2,805,413 | 10 Dec, 2021 |
| Venture Fund Xi, L.P. Atlas | - | 2,019,563 | 734,546 | 09 Feb, 2024 |
| Venture Investments, Llc Alexandria | - | 166,423 | 0 | 26 Oct, 2021 |
| Rene Russo | President And Ceo | 325,422 | 0 | 05 Jan, 2026 |
| Venture Fund Iv, L.P. Rivervest | - | 0 | 1,441,444 | 26 Oct, 2021 |
| Kgaa Merck | - | 0 | 680,825 | 26 Oct, 2021 |
| Impact Medicine Fund Lp Sv7 | - | 1,613,632 | 1,613,632 | 03 Nov, 2021 |
| Kevin M. Brennan | Svp, Finance And Accounting | 6,371 | 0 | 05 Jan, 2026 |
| Christopher James Frankenfield | Chief Financial Officer | 24,766 | 0 | 05 Jan, 2026 |
| Katarina Luptakova | Chief Medical Officer | 33,250 | 0 | 05 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 15 Apr, 2026 | Cheryl R Blanchard | Stock Option (right to buy) | A | 10,000 | $0.00 | 10,000 | D | A |
| 26 Mar, 2026 | James Samuel Shannon | Common Stock | A | 5,000 | $8.79 | 10,000 | D | P |
| 13 Feb, 2026 | Sciences, Inc. Gilead | Prefunded Warrants (right to buy) | A | 3,739,000 | $0.53 | 40,384,266 | D | P |
| 01 Jan, 2026 | Katarina Luptakova | Common Stock | A | 16,625 | - | 33,250 | D | M |
| 01 Jan, 2026 | Rene Russo | Common Stock | A | 44,250 | - | 325,422 | D | M |
| 01 Jan, 2026 | Christopher James Frankenfield | Common Stock | A | 19,375 | - | 31,796 | D | M |
| 01 Jan, 2026 | Kevin M. Brennan | Common Stock | A | 5,000 | - | 8,197 | D | M |
| 02 Jan, 2026 | Kevin M. Brennan | Common Stock | D | 1,826 | $0.64 | 6,371 | D | S |
| 31 Dec, 2025 | Rene Russo | Stock Option (right to buy) | A | 1,500,258 | $0.00 | 1,500,258 | D | A |
| 31 Dec, 2025 | Katarina Luptakova | Stock Option (right to buy) | A | 451,885 | $0.00 | 451,885 | D | A |
| 02 Jan, 2026 | Christopher James Frankenfield | Common Stock | D | 7,030 | $0.64 | 24,766 | D | S |
| 31 Dec, 2025 | Christopher James Frankenfield | Stock Option (right to buy) | A | 668,789 | $0.00 | 668,789 | D | A |
| 01 Jan, 2026 | Rene Russo | Restricted Stock Units | D | 44,250 | $0.00 | 88,500 | D | M |
| 31 Dec, 2025 | Kevin M. Brennan | Stock Option (right to buy) | A | 95,221 | $0.00 | 95,221 | D | A |
| 01 Jan, 2026 | Katarina Luptakova | Restricted Stock Units | D | 16,625 | $0.00 | 33,250 | D | M |
| 01 Jan, 2026 | Christopher James Frankenfield | Restricted Stock Units | D | 19,375 | $0.00 | 38,750 | D | M |
| 01 Jan, 2026 | Kevin M. Brennan | Restricted Stock Units | D | 5,000 | $0.00 | 10,000 | D | M |
| 26 Nov, 2025 | Sciences, Inc. Gilead | Prefunded Warrants (right to buy) | A | 13,335,000 | $0.75 | 36,645,266 | D | X |
| 26 Nov, 2025 | Sciences, Inc. Gilead | Series B Warrants (right to buy) | D | 13,335,000 | $0.00 | 0 | D | X |
| 21 Nov, 2025 | Christopher James Frankenfield | Stock Option (right to buy) | A | 925,000 | $0.00 | 925,000 | D | A |